Trials / Completed
CompletedNCT03647215
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
A Cohort Study To Establish the Prevalence of Mutations in Patients With CML Who Meet the ELN Criteria for Warning or Failure and Patients With Ph+ ALL With Detectable BCR-ABL Currently Being Treated With First or Subsequent TKI Therapy in the UK, Ireland, or France Using Next-Generation Sequencing
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 427 (actual)
- Sponsor
- Incyte Biosciences UK · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, prospective cohort study of the mutation status of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are being treated with first or subsequent tyrosine kinase inhibitor (TKI) therapy in the UK, Ireland, or France.
Conditions
- Chronic Phase Chronic Myelogenous Leukemia
- Accelerated Phase Chronic Myelogenous Leukemia
- Blastic Phase Chronic Myelogenous Leukemia
- Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Timeline
- Start date
- 2017-12-18
- Primary completion
- 2021-03-31
- Completion
- 2021-06-30
- First posted
- 2018-08-27
- Last updated
- 2021-08-16
Locations
33 sites across 2 countries: Ireland, United Kingdom
Source: ClinicalTrials.gov record NCT03647215. Inclusion in this directory is not an endorsement.